Alogliptin combinations filed for Japanese approval
This article was originally published in Scrip
Executive Summary
Takeda has submitted marketing applications in Japan for its DPP-4 inhibitor alogliptin as a concomitant therapy with thiazolidinedione (TZD) antidiabetics, and also in a fixed-dose combination with its own TZD, pioglitazone.